CoChat
Sign Up
Cited by 268Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease

Open access
Dumanski, Jan P., Lambert, Jean-Charles, Rasi, Chiara, Giedraitis, Vilmantas, Davies, Hanna, Grenier-Boley, Benjamin, Lindgren, Cecilia M., Campion, Dominique, Dufouil, Carole, Pasquier, Florence, Amouyel, Philippe, Lannfelt, Lars, Ingelsson, Martin, Kilander, Lena, Lind, Lars, Forsberg, Lars A.·2016·The American Journal of Human Genetics
DOI 10.1016/j.ajhg.2016.05.014PMC PMC4908225
Open this paper in CoChat — free accountOpen PDF

Abstract

Men have a shorter life expectancy compared with women but the underlying factor(s) are not clear. Late-onset, sporadic Alzheimer disease (AD) is a common and lethal neurodegenerative disorder and many germline inherited variants have been found to influence the risk of developing AD. Our previous results show that a fundamentally different genetic variant, i.e., lifetime-acquired loss of chromosome Y (LOY) in blood cells, is associated with all-cause mortality and an increased risk of non-hematological tumors and that LOY could be induced by tobacco smoking. We tested here a hypothesis that men with LOY are more susceptible to AD and show that LOY is associated with AD in three independent studies of different types. In a case-control study, males with AD diagnosis had higher degree of LOY mosaicism (adjusted odds ratio = 2.80, p = 0.0184, AD events = 606). Furthermore, in two prospective studies, men with LOY at blood sampling had greater risk for incident AD diagnosis during follow-up time (hazard ratio [HR] = 6.80, 95% confidence interval [95% CI] = 2.16-21.43, AD events = 140, p = 0.0011). Thus, LOY in blood is associated with risks of both AD and cancer, suggesting a role of LOY in blood cells on disease processes in other tissues, possibly via defective immunosurveillance. As a male-specific risk factor, LOY might explain why males on average live shorter lives than females.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajhg.2016.05.014

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Reproducible Estimations of LOY via Two Independent Technologies Validation of LOY mosaicism detected by SNP-array data by whole-genome next-generation sequencing (WGS) in 183 EADI1 participants. This was performed by estimating ploidy values from about 30× NGS data using the FREEC software.46
Figure 1 Reproducible Estimations of LOY via Two Independent Technologies Validation of LOY mosaicism detected by SNP-array data by whole-genome next-generation sequencing (WGS) in 183 EADI1 participants. This was performed by estimating ploidy values from about 30× NGS data using the FREEC software.46CC BY-NC-ND · PubMed Central
Figure 2 Mosaic LOY in Blood Cells Increases with Participant Sampling Age (A) Illustration of the association between of LOY and age of sampling in all 3,218 subjects from three independent cohorts included in the analyses. Linear regression shows that LOY (i.e., mLRRY) was associated with sampling age (ANOVA; F(1,3216) = 26.79, p < 0.0001). (B–D) Corresponding plots of the data from ULSAM (B), PIVUS (C), and EADI1 (D) cohorts. The dotted horizontal lines show the cut-off used for LOY scoring at the 99% confidence interval in the three independent cohorts. (E) The increasing degree of LOY in four different age groups in the three included studies and p values adjusted for multiple testing using Tukey’s method is shown. The whiskers extend to illustrate the 1.5 inter-quantile range of the total variation in each age group. (F) Summary of the observed frequencies of LOY in the different age groups plotted in (E).
Figure 2 Mosaic LOY in Blood Cells Increases with Participant Sampling Age (A) Illustration of the association between of LOY and age of sampling in all 3,218 subjects from three independent cohorts included in the analyses. Linear regression shows that LOY (i.e., mLRRY) was associated with sampling age (ANOVA; F(1,3216) = 26.79, p < 0.0001). (B–D) Corresponding plots of the data from ULSAM (B), PIVUS (C), and EADI1 (D) cohorts. The dotted horizontal lines show the cut-off used for LOY scoring at the 99% confidence interval in the three independent cohorts. (E) The increasing degree of LOY in four different age groups in the three included studies and p values adjusted for multiple testing using Tukey’s method is shown. The whiskers extend to illustrate the 1.5 inter-quantile range of the total variation in each age group. (F) Summary of the observed frequencies of LOY in the different age groups plotted in (E).CC BY-NC-ND · PubMed Central
Figure 3 Men Diagnosed with Alzheimer Disease Had on Average a Higher Level of LOY in Blood Cells Compared to AD-free Controls (A and B) Unadjusted and adjusted analyses performed in the case-control EADI1 study (n = 1,611). Men with AD had significantly higher level of LOY compared to controls (A, unadjusted Kolmogorov-Smirnov test: D = 0.07, p = 0.0198). Difference in LOY between subjects with AD and controls by plotting the adjusted residuals from an ANCOVA model fitting the effects from sampling age and APOE genotype (B). Also in this model subjects with AD diagnosis had a significantly higher level of LOY in blood compared to the control subjects (ANCOVA: F(1,1604) = 5.63, p = 0.0178). (C and D) Results from analogous comparisons after pooling data from three independent cohorts, i.e., EADI1, ULSAM, and PIVUS (n = 3,218) and a significant difference in mLRRY values between all men with AD diagnosis (prevalent and incident) compared to control subjects in unadjusted (C, Kolmogorov-Smirnov test: D = 0.05, p = 0.0390) as well as adjusted (D, ANCOVA: F(1,3085) = 7.44, p = 0.0064) tests. In (D) we plotted the adjusted residuals using the same method as described for (B). (E–H) Levels of LOY observed in men with and without AD diagnosis (prevalent and incident) in the ULSAM (E) and PIVUS (F) cohorts separately as well as pooled together (G) and after removing subjects diagnosed with cancer (H). The whiskers in all boxplots extend to illustrate the 1.5 inter-quantile range of the total variation in each group.
Figure 3 Men Diagnosed with Alzheimer Disease Had on Average a Higher Level of LOY in Blood Cells Compared to AD-free Controls (A and B) Unadjusted and adjusted analyses performed in the case-control EADI1 study (n = 1,611). Men with AD had significantly higher level of LOY compared to controls (A, unadjusted Kolmogorov-Smirnov test: D = 0.07, p = 0.0198). Difference in LOY between subjects with AD and controls by plotting the adjusted residuals from an ANCOVA model fitting the effects from sampling age and APOE genotype (B). Also in this model subjects with AD diagnosis had a significantly higher level of LOY in blood compared to the control subjects (ANCOVA: F(1,1604) = 5.63, p = 0.0178). (C and D) Results from analogous comparisons after pooling data from three independent cohorts, i.e., EADI1, ULSAM, and PIVUS (n = 3,218) and a significant difference in mLRRY values between all men with AD diagnosis (prevalent and incident) compared to control subjects in unadjusted (C, Kolmogorov-Smirnov test: D = 0.05, p = 0.0390) as well as adjusted (D, ANCOVA: F(1,3085) = 7.44, p = 0.0064) tests. In (D) we plotted the adjusted residuals using the same method as described for (B). (E–H) Levels of LOY observed in men with and without AD diagnosis (prevalent and incident) in the ULSAM (E) and PIVUS (F) cohorts separately as well as pooled together (G) and after removing subjects diagnosed with cancer (H). The whiskers in all boxplots extend to illustrate the 1.5 inter-quantile range of the total variation in each group.CC BY-NC-ND · PubMed Central
Figure 4 Cox Proportional Hazards Regression Models Adjusting for Potential Confounders Show that Men with Mosaic LOY at Blood Cells at Time for Sampling Were More Likely to Be Diagnosed with AD during the Follow-up Time Probabilities for AD-free follow-up time are illustrated using red and black curves for men with and without LOY, respectively. Participants were scored as with or without LOY using two defined thresholds. Participants with an mLRRY value lower than the 99% confidence limit of the experimental variation were scored with LOY (A and B) and a threshold at mLRRY ≤ −0.4 was used (C and D). The analyses were performed using pooled data from the ULSAM and PIVUS studies. Shown are analyses with all men (A and C; n = 1,599, AD events = 140) and analogous analyses after excluding men with any cancer (B and D; n = 990, AD events = 104). The effects from all confounders in the models are given in Tables S4, S5, S7, and S8.
Figure 4 Cox Proportional Hazards Regression Models Adjusting for Potential Confounders Show that Men with Mosaic LOY at Blood Cells at Time for Sampling Were More Likely to Be Diagnosed with AD during the Follow-up Time Probabilities for AD-free follow-up time are illustrated using red and black curves for men with and without LOY, respectively. Participants were scored as with or without LOY using two defined thresholds. Participants with an mLRRY value lower than the 99% confidence limit of the experimental variation were scored with LOY (A and B) and a threshold at mLRRY ≤ −0.4 was used (C and D). The analyses were performed using pooled data from the ULSAM and PIVUS studies. Shown are analyses with all men (A and C; n = 1,599, AD events = 140) and analogous analyses after excluding men with any cancer (B and D; n = 990, AD events = 104). The effects from all confounders in the models are given in Tables S4, S5, S7, and S8.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

Sorted by citations

See all 268

Related

Metadata

Authors
Dumanski, J. P., Lambert, J.-C., Rasi, C., Giedraitis, V., Davies, H., Grenier-Boley, B., Lindgren, C. M., Campion, D., Dufouil, C., Pasquier, F., Amouyel, P., Lannfelt, L., Ingelsson, M., Kilander, L., Lind, L., & Forsberg, L. A.
Affiliations
  • Uppsala University (SE)
  • Inserm (FR)
  • Broad Institute (US)
Corresponding author
  • Dumanski, Jan P.
  • Forsberg, Lars A.
ORCID
Venue
The American Journal of Human Genetics
Publisher
Elsevier BV
Published
2016-06
Volume
98
Issue
6
Pages
1208-1219
ISSN
0002-9297 (ISSN-L)
DOI
10.1016/j.ajhg.2016.05.014
PMC
PMC4908225
OpenAlex
W2403642712
Cited by
266
References
65
Citations by year
2026: 35 · 2025: 42 · 2024: 33 · 2023: 33 · 2022: 22 · 2021: 33 · 2020: 19 · 2019: 22 · 2018: 14 · 2017: 10 · 2016: 3
FWCI
14.51
Type
journal article
Language
en
Open access
Licence
Locations
  • The American Journal of Human Genetics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (WT098017, 086596, 086596/Z/08/Z, WT064890, WT090532)
  • Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease
  • Agence Nationale de la Recherche (ANR-11-LABX-0009)
  • Cancerfonden
  • Hjärt-Lungfonden
  • Vetenskapsrådet
  • Akademiska Sjukhuset
  • Uppsala Universitet
  • Science for Life Laboratory
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
Keywords
Y chromosome mosaicism, Alzheimer's disease, sex differences in mortality, blood cells, cancer risk, immune surveillance, smoking, all-cause mortality
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Longitudinal Studies, Male, Middle Aged, Mosaicism, Prognosis, Prospective Studies, Risk Factors, Case-Control Studies, Polymorphism, Single Nucleotide, Chromosomes, Human, Y

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review